"The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma"...
Side effects of photopheresis (UVADEX™ used with the THERAKOS™ Photopheresis System) were primarily related to hypotension secondary to changes in extracorporeal volume ( > 1%). In study CTCL 3 (UVADEX™), six serious cardiovascular adverse experiences were reported in five patients (5/51, 10%). Five of these six events were not related to photopheresis and did not interfere with the scheduled photopheresis treatments. One patient (1/51, 2%) with ischemic heart disease had an arrhythmia after the first day of photopheresis that was resolved the next day. Six infections were also reported in five patients. Two of the six events were Hickman catheter infections in one patient, which did not interrupt the scheduled photopheresis. The other four infections were not related to photopheresis and did not interfere with scheduled treatments.
An analysis of postmarketing data shows the following events occurred with an incidence of < 0.01%: rash, allergic reaction, pyrexia, nausea, dysgeusia.
Read the Uvadex (methoxsalen) Side Effects Center for a complete guide to possible side effects
Additional Uvadex Information
- Uvadex Drug Interactions Center: methoxsalen inj
- Uvadex Side Effects Center
- Uvadex Overview including Precautions
- Uvadex FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
Get the latest treatment options.